2001-32-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-nitrophenyl)propionic acid is used as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis. It operates by inhibiting the production of prostaglandins, which are chemicals responsible for causing pain and inflammation in the body.
Used in Pain Management:
3-(2-nitrophenyl)propionic acid is used as a pain reliever to alleviate discomfort associated with various conditions, including but not limited to musculoskeletal disorders.
Used in Inflammation Reduction:
3-(2-nitrophenyl)propionic acid is utilized as an anti-inflammatory to reduce inflammation, which is a common symptom in several medical conditions.
However, due to its potential side effects, such as gastrointestinal irritation, renal toxicity, and an increased risk of cardiovascular events, the use of 3-(2-nitrophenyl)propionic acid should be carefully monitored by healthcare professionals.

InChI:InChI=1/C9H9NO4/c11-9(12)6-5-7-3-1-2-4-8(7)10(13)14/h1-4H,5-6H2,(H,11,12)

Upstream product

• 16793-89-8 (2-bromoethyl)-2-nitrobenzene 
• 151-50-8 potassium cyanide 
• 501-52-0 3-Phenylpropionic acid 
• 612-23-7 2-nitrobenzyl chloride 
• 105-53-3 diethyl malonate 
• 7697-37-2 nitric acid 
• 7647-01-0 hydrogenchloride 
• 59803-35-9 (2-nitro-benzyl)-malonic acid diethyl ester 
• 859197-37-8 dimethyl 2-(2-nitrobenzyl)-malonate 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 612-25-9 2-Nitrobenzyl alcohol 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 2033-24-1 cycl-isopropylidene malonate 
• 552-89-6 2-nitro-benzaldehyde 

Downstream Products

• 33100-15-1 2-(2-aminoethyl)nitrobenzene 
• 18910-10-6 α-bromo-β-(2-nitrophenyl)propionic acid 
• 1664-65-9 3-(2-nitrophenyl)propionic acid methyl ester 
• 48108-93-6 β-(o-aminophenyl)ethylamine 
• 24623-25-4 4-nitro-2,3-dihydro-1H-inden-1-one 
• 1014977-73-1 N-(4-chlorobenzyl)-3-(2-nitrophenyl)propionamide 
• 1190966-95-0 1-[4-(4-fluorobenzyl)piperazin-1-yl]-3-(2-nitrophenyl)propan-1-one 
• 1426535-45-6 C₂₆H₂₁F₃N₄O₅S 
• 1426535-37-6 C₃₀H₃₅NO₈ 
• 20716-26-1 3-(2-nitro-phenyl)-propan-1-ol 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy

Cisplatin is one of the most successful antitumor agents, yet also restricted by its poor cellular uptake and low selectivity. Since 3-(2-nitrophenyl) propionic acid (NPPA) has been reported as a bioreductive prodrug moiety, herein we combined NPPA with cisplatin (compound 1) to improve its lipophilicity and targetability and then to improve the antitumor outcomes. In addition, compound 2 possessing 3-phenyl propionic acid (PPA) was also synthesized as a comparison to test the influence of the NPPA to the cytotoxicity, since PPA was not a bioreductive moiety. Bioevaluations showed that 1 displayed more potent antitumor potency than cisplatin and 2, suggesting Pt(II) complexes possessing NPPA groups may be a good strategy for future platinum drug discovery.

NovelN-transfer reagent for converting α-amino acid derivatives to α-diazo compounds

A novel universalN-transfer reagent for direct and effective transformation of α-amino ketones, acetamides, and esters to the corresponding α-diazo products under mild basic conditions has been developed. This one-step synthetic approach not only allows for generation of α-substituted-α-diazo carbonyl compounds from α-amino acid derivatives but also permits preparation of α-diazo dipeptides fromN-terminal dipeptides (32 examples, up to 91%).

N-transfer reagent and method for preparing the same and its application

Provided are a novel N-transfer reagent and a method for preparing the same and its application. The N-transfer reagent is represented by the following Formula (I): The various novel N-transfer reagents of the present invention can be quickly prepared by employing different nitrobenzene precursors. The N-transfer reagents can directly convert a variety of amino compounds into diazo compounds under mild conditions. Particularly, the N-transfer reagents can facilitate the synthesis of the diazo compounds. The application of synthesizing diazo compounds of the present invention can greatly decrease the difficulty in operation, increase the safety during experiments, reduce the cost of production and the environmental pollution, and enhance the industrial value of diazo compounds.

Deconstructive di-functionalization of unstrained, benzo cyclic amines by C-N bond cleavage using a recyclable tungsten catalyst

With H2WO4 as the catalyst and H2O2 as the oxidant, we herein report a deconstructive difunctionalization of the C-N bond in unstrained, benzo cyclic amines to generate an ester group and nitro group simultaneously. The preliminary mechanistic studies suggested that the corresponding hydroxamic acid is the key intermediate for this transformation. Importantly, with the utilization of this transformation, we achieved an interesting approach for the ring contraction of quinoline to indole, an example of scaffold hopping in a hetero-aromatic system.

Synthesis of isomeric (3,3,3-trifluoropropyl)anilines

Ortho-, meta- and para-isomers of (3,3,3-trifluoropropyl)aniline have been prepared in 60-70 g amount from the corresponding nitrobenzaldehydes in three steps. The key synthesis step was a transformation of the carboxylic group of 3-(nitrophenyl)propanoic acids into the trifluoromethyl group by SF4.

A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib

Celecoxib is a COX-2 inhibitor drug that can be used to reduce the risk of colorectal adenocarcinoma. Glucocorticoids are used in the treatment of inflammatory bowel disease. A limitation to the use of both drug types is that they undergo absorption from the intestinal tract with serious side effects. The prodrug systems introduced here involve forming a nitro-substituted acylsulfonamide group in the case of celecoxib and a nitro-substituted 21-ester for the glucocorticoids. Drug release is triggered by the nitro reductase action of the colonic microflora, liberating a cyclization competent species. The release of the active parent drugs was evaluated in vitro using Clostridium perfringens and epithelial transport through Caco-2 monolayer evaluation was carried out to estimate the absorption properties of the prodrugs compared to the parental drugs.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES

This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). BHC 03 2 001-Foreign-Countries - 66 - BHC 03 2 001-Foreign-Countries - 65 -

Nitric acid in the presence of P2O5 supported on silica gel - A useful reagent for nitration of aromatic compounds under solvent-free conditions

A variety of aromatic compounds are nitrated to parent nitro aromatic compounds under solvent-free conditions using 65% nitric acid in the presence of P2O5 supported on silica gel is described. This methodology is useful for nitration of activated and deactivated aromatic rings.

TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES

This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.